Pages that link to "Q73615496"
Jump to navigation
Jump to search
The following pages link to Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy (Q73615496):
Displaying 50 items.
- Secondary prevention of recurrence by interferon therapy after ablation therapy for hepatocellular carcinoma in chronic hepatitis C patients (Q24653596) (← links)
- High versus standard doses interferon-alpha in the treatment of naïve chronic hepatitis C patients in Taiwan: a 10-year cohort study (Q24799492) (← links)
- Natural regression of fibrosis in chronic hepatitis B (Q26746929) (← links)
- Recent advances in managing chronic HCV infection: focus on therapy in patients with severe liver disease (Q26752433) (← links)
- KASL clinical practice guidelines: management of hepatitis C (Q26752471) (← links)
- Imaging Based Methods of Liver Fibrosis Assessment in Viral Hepatitis: A Practical Approach (Q26771433) (← links)
- Chronic hepatitis C: This and the new era of treatment (Q26775011) (← links)
- Prediction of fibrosis progression in chronic viral hepatitis (Q26823671) (← links)
- Smad3 phospho-isoform signaling in hepatitis C virus-related chronic liver diseases (Q26863522) (← links)
- Hepatocellular carcinoma in patients with chronic hepatitis C virus infection in the Asia-Pacific region (Q27026753) (← links)
- A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C (Q27482028) (← links)
- Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: A 5-year follow-up of 150 patients (Q27489398) (← links)
- Antiviral therapy in hepatitis C virus cirrhotic patients in compensated and decompensated condition (Q27490340) (← links)
- Molecular mechanism and treatment of viral hepatitis-related liver fibrosis (Q27692609) (← links)
- Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges (Q28272678) (← links)
- Analysis of the virus dynamics model reveals that early treatment of HCV infection may lead to the sustained virological response (Q28481489) (← links)
- Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C (Q30235178) (← links)
- APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. (Q30250088) (← links)
- Magnetic resonance elastography in a rabbit model of liver fibrosis: a 3-T longitudinal validation for clinical translation (Q30368978) (← links)
- Changes of shear-wave velocity by interferon-based therapy in chronic hepatitis C. (Q30402571) (← links)
- Prediction of hepatocellular carcinoma incidence risk by ultrasound elastography (Q30438860) (← links)
- Cellular mechanisms of tissue fibrosis. 1. Common and organ-specific mechanisms associated with tissue fibrosis. (Q30443462) (← links)
- A serum "sweet-doughnut" protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis (Q30459124) (← links)
- Magnetic resonance elastography of the kidneys: Feasibility and reproducibility in young healthy adults (Q30463019) (← links)
- Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma (Q30479629) (← links)
- Clinical significance of alanine aminotransferase levels and the effect of ursodeoxycholic acid in hemodialysis patients with chronic hepatitis C. (Q33386956) (← links)
- Association between IPTA gene polymorphisms and hematological abnormalities in hepatitis C virus-infected patients receiving combination therapy (Q33418008) (← links)
- Efficacy and safety of dual therapy with daclatasvir and asunaprevir in elderly patients (Q33576524) (← links)
- Diagnostic value of gadobenate dimeglumine-enhanced hepatocyte-phase magnetic resonance imaging in evaluating hepatic fibrosis and hepatitis (Q33652009) (← links)
- Interferon augments the anti-fibrotic activity of an angiotensin-converting enzyme inhibitor in patients with refractory chronic hepatitis C. (Q33866293) (← links)
- Usefulness of noninvasive transient elastography for assessment of liver fibrosis stage in chronic hepatitis C (Q33866681) (← links)
- Long-term outcomes of chronic hepatitis C patients with sustained virological response at 6 months after the end of treatment (Q33869545) (← links)
- No association between the IL28B SNP and response to peginterferon plus ribavirin combination treatment in Korean chronic hepatitis C patients (Q33905607) (← links)
- Postoperative adjuvant antiviral therapy for hepatitis B/C virus-related hepatocellular carcinoma: a meta-analysis (Q33920626) (← links)
- Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials (Q33947375) (← links)
- Acute and chronic immune biomarker changes during interferon/ribavirin treatment in HIV/HCV co-infected patients (Q34022134) (← links)
- TGF-β/Smad signaling during hepatic fibro-carcinogenesis (review). (Q34120419) (← links)
- Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma (Q34225588) (← links)
- Hepatic fibrosis. Pathogenesis and principles of therapy (Q34269628) (← links)
- Non-invasive assessment of changes in liver fibrosis via liver stiffness measurement in patients with chronic hepatitis B: impact of antiviral treatment on fibrosis regression (Q34365464) (← links)
- Long-Term Effects of Antiviral Therapy in Patients with Chronic Hepatitis C (Q34415157) (← links)
- Effects and outcomes of interferon treatment in Japanese hepatitis C patients (Q34443253) (← links)
- Long-term outcome of chronic hepatitis C patients with sustained virological response to peginterferon plus ribavirin (Q34521418) (← links)
- Nonresponse to interferon-α based treatment for chronic hepatitis C infection is associated with increased hazard of cirrhosis (Q34700417) (← links)
- LecT-Hepa facilitates estimating treatment outcome during interferon therapy in chronic hepatitis C patients. (Q34769512) (← links)
- Predictors of spontaneous viral clearance and outcomes of acute hepatitis C infection (Q34779758) (← links)
- Constitutional telomerase mutations are genetic risk factors for cirrhosis (Q34862975) (← links)
- Introduction to therapy of hepatitis C. (Q34984075) (← links)
- Treatment of chronic hepatitis C: a systematic review (Q34984085) (← links)
- Hepatic gene expression profiles associated with fibrosis progression and hepatocarcinogenesis in hepatitis C patients (Q35010547) (← links)